BACKGROUND: Chemoradiation (CRT) can significantly modify the radiographic appearance of malignant gliomas, especially within the immediate post-CRT period. Pseudoprogression (PsP) is an increasingly recognized phenomenon in this setting, and is thought to be secondary to increased permeability as a byproduct of the complex process of radiation-induced tissue injury, possibly enhanced by temozolomide. We sought to determine whether the addition of a vascular endothelial growth factor (VEGF) signaling inhibitor (cediranib) to conventional CRT had an impact on the frequency of PsP, by comparing two groups of patients with newly diagnosed glioblastoma before, during, and after CRT. METHODS: All patients underwent serial magnetic resonance imaging as part of institutional review board-approved clinical studies. Eleven patients in the control group received only chemoradiation, whereas 29 patients in the study group received chemoradiation and cediranib until disease progression or toxicity. Response assessment was defined according to Response Assessment in Neuro-Oncology criteria, and patients with enlarging lesions were classified into true tumor progressions (TTP) or PsP, based on serial radiographic follow-up. RESULTS: Two patients in the study group (7%) showed signs of apparent early tumor progression, and both were subsequently classified as TTP. Six patients in the control group (54%) showed signs of apparent early tumor progression, and three were subsequently classified as TTP and three as PsP. The frequency of PsP was significantly higher in the control group. CONCLUSION: Administration of a VEGF inhibitor during and after CRT modifies the expression of PsP by imaging.
BACKGROUND: Chemoradiation (CRT) can significantly modify the radiographic appearance of malignant gliomas, especially within the immediate post-CRT period. Pseudoprogression (PsP) is an increasingly recognized phenomenon in this setting, and is thought to be secondary to increased permeability as a byproduct of the complex process of radiation-induced tissue injury, possibly enhanced by temozolomide. We sought to determine whether the addition of a vascular endothelial growth factor (VEGF) signaling inhibitor (cediranib) to conventional CRT had an impact on the frequency of PsP, by comparing two groups of patients with newly diagnosed glioblastoma before, during, and after CRT. METHODS: All patients underwent serial magnetic resonance imaging as part of institutional review board-approved clinical studies. Eleven patients in the control group received only chemoradiation, whereas 29 patients in the study group received chemoradiation and cediranib until disease progression or toxicity. Response assessment was defined according to Response Assessment in Neuro-Oncology criteria, and patients with enlarging lesions were classified into true tumor progressions (TTP) or PsP, based on serial radiographic follow-up. RESULTS: Two patients in the study group (7%) showed signs of apparent early tumor progression, and both were subsequently classified as TTP. Six patients in the control group (54%) showed signs of apparent early tumor progression, and three were subsequently classified as TTP and three as PsP. The frequency of PsP was significantly higher in the control group. CONCLUSION: Administration of a VEGF inhibitor during and after CRT modifies the expression of PsP by imaging.
Authors: James J Vredenburgh; Annick Desjardins; John P Kirkpatrick; David A Reardon; Katherine B Peters; James E Herndon; Jennifer Marcello; Leighann Bailey; Stevie Threatt; John Sampson; Allan Friedman; Henry S Friedman Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-30 Impact factor: 7.038
Authors: A Gregory Sorensen; Kyrre E Emblem; Pavlina Polaskova; Dominique Jennings; Heisoog Kim; Marek Ancukiewicz; Meiyun Wang; Patrick Y Wen; Percy Ivy; Tracy T Batchelor; Rakesh K Jain Journal: Cancer Res Date: 2011-11-29 Impact factor: 12.701
Authors: Tracy T Batchelor; Elizabeth R Gerstner; Kyrre E Emblem; Dan G Duda; Jayashree Kalpathy-Cramer; Matija Snuderl; Marek Ancukiewicz; Pavlina Polaskova; Marco C Pinho; Dominique Jennings; Scott R Plotkin; Andrew S Chi; April F Eichler; Jorg Dietrich; Fred H Hochberg; Christine Lu-Emerson; A John Iafrate; S Percy Ivy; Bruce R Rosen; Jay S Loeffler; Patrick Y Wen; A Greg Sorensen; Rakesh K Jain Journal: Proc Natl Acad Sci U S A Date: 2013-11-04 Impact factor: 11.205
Authors: Tracy T Batchelor; Paul Mulholland; Bart Neyns; L Burt Nabors; Mario Campone; Antje Wick; Warren Mason; Tom Mikkelsen; Surasak Phuphanich; Lynn S Ashby; John Degroot; Rao Gattamaneni; Lawrence Cher; Mark Rosenthal; Franz Payer; Juliane M Jürgensmeier; Rakesh K Jain; A Gregory Sorensen; John Xu; Qi Liu; Martin van den Bent Journal: J Clin Oncol Date: 2013-08-12 Impact factor: 44.544
Authors: Wolfgang Wick; Michael Platten; Christoph Meisner; Jörg Felsberg; Ghazaleh Tabatabai; Matthias Simon; Guido Nikkhah; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Stephanie E Combs; Jan Vesper; Christian Braun; Jürgen Meixensberger; Ralf Ketter; Regine Mayer-Steinacker; Guido Reifenberger; Michael Weller Journal: Lancet Oncol Date: 2012-05-10 Impact factor: 41.316
Authors: Jayashree Kalpathy-Cramer; Elizabeth R Gerstner; Kyrre E Emblem; Ovidiu Andronesi; Bruce Rosen Journal: Cancer Res Date: 2014-09-01 Impact factor: 12.701
Authors: M A Prah; S M Stufflebeam; E S Paulson; J Kalpathy-Cramer; E R Gerstner; T T Batchelor; D P Barboriak; B R Rosen; K M Schmainda Journal: AJNR Am J Neuroradiol Date: 2015-06-11 Impact factor: 3.825
Authors: Giorgio Seano; Hadi T Nia; Kyrre E Emblem; Meenal Datta; Jun Ren; Shanmugarajan Krishnan; Jonas Kloepper; Marco C Pinho; William W Ho; Mitrajit Ghosh; Vasileios Askoxylakis; Gino B Ferraro; Lars Riedemann; Elizabeth R Gerstner; Tracy T Batchelor; Patrick Y Wen; Nancy U Lin; Alan J Grodzinsky; Dai Fukumura; Peigen Huang; James W Baish; Timothy P Padera; Lance L Munn; Rakesh K Jain Journal: Nat Biomed Eng Date: 2019-01-07 Impact factor: 25.671